Aleor Dermaceuticals, a 60:40 joint venture between Alembic Pharmaceuticals and Orbicular Pharmaceutical Technologies Pvt Ltd, has received an establishment inspection report from the United States Food and Drug Administration. The US drug authority had carried out the inspection at Aleor's formulation facility at Karakhadi, Gujarat, between September 16 and 20. The stock of Alembic Pharma may react positively to the development, as EIR is seen as good for the establishment.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.